Lixte Biotechnology (NASDAQ:LIXT) Stock Price Up 12.1% – Still a Buy?

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) shares rose 12.1% during mid-day trading on Tuesday . The stock traded as high as $5.49 and last traded at $5.27. Approximately 74,604 shares changed hands during mid-day trading, an increase of 7% from the average daily volume of 69,553 shares. The stock had previously closed at $4.70.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lixte Biotechnology in a report on Tuesday, May 12th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Lixte Biotechnology Stock Performance

The stock has a market capitalization of $73.17 million, a price-to-earnings ratio of -5.23 and a beta of 1.04. The company has a fifty day simple moving average of $3.66 and a two-hundred day simple moving average of $3.67.

Lixte Biotechnology (NASDAQ:LIXT) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.18) earnings per share for the quarter.

Hedge Funds Weigh In On Lixte Biotechnology

A number of institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC raised its holdings in shares of Lixte Biotechnology by 47.0% during the 4th quarter. Renaissance Technologies LLC now owns 107,500 shares of the company’s stock worth $422,000 after buying an additional 34,350 shares in the last quarter. Federation des caisses Desjardins du Quebec raised its holdings in shares of Lixte Biotechnology by 83.6% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock worth $367,000 after buying an additional 42,530 shares in the last quarter. DRW Securities LLC raised its holdings in shares of Lixte Biotechnology by 11.6% during the 4th quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock worth $213,000 after buying an additional 5,645 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Lixte Biotechnology by 25.9% during the 4th quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock worth $205,000 after buying an additional 10,722 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Lixte Biotechnology during the 4th quarter worth $57,000. Institutional investors and hedge funds own 5.10% of the company’s stock.

About Lixte Biotechnology

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.